See more : Karadanote Inc. (4014.T) Income Statement Analysis – Financial Results
Complete financial analysis of Adjuvant Holdings Co.,Ltd. (4929.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adjuvant Holdings Co.,Ltd., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- R.P.P. Infra Projects Limited (RPPINFRA.NS) Income Statement Analysis – Financial Results
- Sasken Technologies Limited (SASKEN.BO) Income Statement Analysis – Financial Results
- Coca-Cola Bottlers Japan Holdings Inc. (2579.T) Income Statement Analysis – Financial Results
- Sonder Holdings Inc. (SONDW) Income Statement Analysis – Financial Results
- Coventry Group Ltd (CVTYF) Income Statement Analysis – Financial Results
Adjuvant Holdings Co.,Ltd. (4929.T)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.adjuvant.co.jp
About Adjuvant Holdings Co.,Ltd.
Adjuvant Holdings Co.,Ltd. engages in the research, development, production, and sale of cosmetics in Japan. The company offers skin care products, including cleansing products, face washes, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeups, and body care products; hair care products comprising shampoos, treatments, scalp cleansing products, scalp lotions, and styling products; and other products. It serves hairdressing salons, barber shops, and esthetic salons. The company was formerly known as Adjuvant Cosme Japan Co.,Ltd. and changed its name to Adjuvant Holdings Co.,Ltd. in September 2021. Adjuvant Holdings Co.,Ltd. was founded in 1990 and is headquartered in Kobe, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.44B | 4.38B | 4.43B | 4.89B | 4.67B | 5.16B | 5.10B | 4.77B | 4.40B | 4.50B | 4.57B | 4.47B | 4.14B |
| Cost of Revenue | 1.58B | 1.46B | 1.49B | 1.89B | 1.86B | 2.00B | 1.90B | 1.76B | 1.59B | 1.63B | 1.58B | 1.59B | 1.41B |
| Gross Profit | 2.86B | 2.92B | 2.94B | 3.00B | 2.81B | 3.16B | 3.20B | 3.01B | 2.81B | 2.87B | 2.99B | 2.88B | 2.73B |
| Gross Profit Ratio | 64.45% | 66.61% | 66.45% | 61.35% | 60.12% | 61.23% | 62.80% | 63.07% | 63.82% | 63.73% | 65.41% | 64.36% | 65.98% |
| Research & Development | 179.83M | 181.00M | 173.00M | 151.00M | 161.00M | 146.00M | 156.69M | 142.42M | 110.53M | 54.00M | 43.00M | 36.00M | 0.00 |
| General & Administrative | 182.00M | 167.00M | 164.00M | 242.00M | 248.00M | 220.00M | 241.00M | 221.00M | 176.00M | 179.00M | 179.00M | 192.00M | 0.00 |
| Selling & Marketing | 574.00M | 306.00M | 232.00M | 253.00M | 401.00M | 428.00M | 369.00M | 373.00M | 346.00M | 376.00M | 396.00M | 365.00M | 0.00 |
| SG&A | 2.68B | 2.68B | 2.55B | 2.70B | 3.00B | 2.99B | 2.54B | 2.35B | 2.05B | 2.14B | 1.99B | 1.89B | 0.00 |
| Other Expenses | 0.00 | 7.08M | -9.06M | 22.84M | 8.17M | 72.80M | 8.34M | 7.94M | 66.87M | 1.74M | -578.00K | -12.16M | 16.27M |
| Operating Expenses | 2.86B | 2.68B | 2.55B | 2.70B | 2.99B | 2.99B | 2.70B | 2.49B | 2.16B | 2.14B | 1.99B | 1.89B | 1.80B |
| Cost & Expenses | 4.44B | 4.14B | 4.04B | 4.59B | 4.86B | 4.99B | 4.60B | 4.25B | 3.75B | 3.77B | 3.57B | 3.48B | 3.21B |
| Interest Income | 1.08M | 1.28M | 3.85M | 3.90M | 3.82M | 6.21M | 5.18M | 3.84M | 3.46M | 2.24M | 1.52M | 322.00K | 231.00K |
| Interest Expense | 0.00 | 0.00 | 3.85M | 40.00K | 101.00K | 191.00K | 470.00K | 880.00K | 43.00K | 0.00 | 2.04M | 11.08M | 12.79M |
| Depreciation & Amortization | 125.41M | 108.85M | 110.43M | 110.64M | 117.60M | 98.86M | 97.28M | 95.37M | 77.69M | 84.63M | 81.95M | 76.61M | 80.18M |
| EBITDA | 124.00M | 697.06M | 500.79M | 292.22M | -44.61M | 282.07M | 608.54M | 634.89M | 671.79M | 1.18B | 1.09B | 1.06B | 994.66M |
| EBITDA Ratio | 2.79% | 0.42% | 10.44% | 8.92% | -0.66% | 6.79% | 11.90% | 13.09% | 17.91% | 23.09% | 23.89% | 23.79% | 25.06% |
| Operating Income | -1.43M | 232.69M | 390.36M | 292.93M | -184.62M | 169.79M | 500.46M | 519.06M | 647.03M | 733.90M | 1.00B | 988.65M | 938.92M |
| Operating Income Ratio | -0.03% | 5.32% | 8.82% | 6.00% | -3.95% | 3.29% | 9.82% | 10.88% | 14.70% | 16.30% | 21.92% | 22.12% | 22.65% |
| Total Other Income/Expenses | 16.72M | 355.53M | 49.18M | -111.40M | 22.31M | 13.24M | 10.34M | 19.59M | -52.97M | -195.75M | 1.09M | -13.45M | -37.21M |
| Income Before Tax | 15.30M | 588.21M | 439.54M | 181.53M | -162.30M | 183.02M | 510.79M | 538.64M | 594.06M | 538.25M | 1.00B | 975.21M | 901.70M |
| Income Before Tax Ratio | 0.34% | 13.44% | 9.93% | 3.72% | -3.47% | 3.54% | 10.02% | 11.29% | 13.50% | 11.95% | 21.95% | 21.82% | 21.75% |
| Income Tax Expense | 115.16M | 184.57M | 46.36M | 39.15M | 65.62M | 157.96M | 199.77M | 208.11M | 327.96M | 491.21M | 431.44M | 441.92M | 625.45M |
| Net Income | -99.87M | 403.64M | 393.18M | 142.38M | -227.93M | 25.06M | 311.02M | 330.54M | 266.10M | 47.04M | 571.73M | 533.29M | 276.25M |
| Net Income Ratio | -2.25% | 9.22% | 8.88% | 2.91% | -4.88% | 0.49% | 6.10% | 6.93% | 6.05% | 1.04% | 12.51% | 11.93% | 6.66% |
| EPS | -12.49 | 50.46 | 49.13 | 17.83 | -28.63 | 3.16 | 39.32 | 41.72 | 33.83 | 6.08 | 76.10 | 85.92 | 51.34 |
| EPS Diluted | -12.49 | 50.46 | 49.08 | 17.76 | -28.63 | 3.14 | 39.09 | 41.49 | 33.44 | 5.96 | 73.81 | 82.12 | 51.34 |
| Weighted Avg Shares Out | 8.00M | 8.00M | 8.00M | 7.99M | 7.96M | 7.94M | 7.91M | 7.92M | 7.87M | 7.73M | 7.51M | 6.21M | 5.38M |
| Weighted Avg Shares Out (Dil) | 8.00M | 8.00M | 8.01M | 8.02M | 7.96M | 7.98M | 7.96M | 7.97M | 7.96M | 7.89M | 7.75M | 6.49M | 5.38M |
ABIONYX Pharma : Bilan semestriel S2 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
PARIS--(BUSINESS WIRE)--Regulatory News: Au titre du contrat de liquidité confié par la société ABIONYX Pharma (Paris:ABNX) à la Société de Bourse Gilbert Dupont, à la date du 31 décembre 2020, les moyens suivants figuraient au compte de liquidité : Nombre...
TAGRISSO Granted Priority Review in the US for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer
AstraZeneca’s TAGRISSO® (osimertinib) has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Revi
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology's licensing partner Specialised Therapeutics Asia received authorization to market NERLYNX in Malaysia.
Ashvattha Therapeutics Unveils Transformative Dendrimer-based anti-VEGF Treatment for Retinal Diseases at ARVO 2020
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics, a biotech company focused on novel dendrimer-based therapies targeting unmet medical needs in ocular, inflammatory diseases, and oncology, today announced the presentation of four virtual posters and presentations supporting the ongoing development of its proprietary...
Lerner Publishing Group Wins Michael L. Printz Honor and Mildred L. Batchelder Honor
MINNEAPOLIS--(BUSINESS WIRE)--Lerner Publishing Group has received two 2019 American Library Association (ALA) Youth Media Awards. The ALA announced at the Midwinter Meeting in Seattle today that I, Claudia by Mary McCoy is the recipient of a Michael L. Printz Honor,...
Multimedia Plus Launches First Public Demo of INCITE® 5.0 + Introduces Smartphone Version at NRF Booth #4929
NEW YORK--(BUSINESS WIRE)--Retail technology firm Multimedia Plus (www.multimediaplus.com) will be demonstrating the latest version of its INCITE mobile Associate Communications Platform (mACP) and will be launching its smartphone version at NRF 2019: Retail’s Big Show, being held January 13–15, 2019,...
Source: https://incomestatements.info
Category: Stock Reports